GSK2197870A

GSK2197870A is an investigational hexavalent combination vaccine developed by GSK Biologicals. It is designed to provide protection against six major pediatric diseases: diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b (Hib), and Neisseria meningitidis serogroup C (MenC). The vaccine formulation includes diphtheria toxoid, tetanus toxoid, three acellular pertussis antigens (pertussis toxoid, filamentous hemagglutinin, and pertactin), inactivated poliovirus (types 1, 2, and 3), and the capsular polysaccharides of Hib and MenC, both conjugated to tetanus toxoid. GSK2197870A was evaluated in Phase II clinical trials as a primary vaccination course for infants, often studied in conjunction with other pediatric vaccines like pneumococcal conjugate vaccines, to reduce the number of injections required in early childhood immunization schedules.

Other names

DTPa-IPV/Hib-MenC-TT vaccineDTPa-IPV-Hib-MenC vaccine